Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients

Summary

Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients is a clinical trial^[1].

Key Facts

• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's instance of is recorded as clinical trial^[2].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's start time is recorded as +2021-08-01T00:00:00Z^[3].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's end time is recorded as +2021-11-30T00:00:00Z^[4].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's number of participants is recorded as {'unit': '1', 'amount': '+5'}^[5].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's title is recorded as The Safety Evaluation of Ex Vivo Activated Haploidentical Natural Killer Cells (NK) in Recurrent Glioblastoma Multiform Patients (Clinical Trial Phase I)^[6].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+3'}^[7].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's ClinicalTrials.gov ID is recorded as NCT05108012^[8].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+60'}^[9].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's clinical trial phase is recorded as phase I clinical trial^[10].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's research subject recruitment status is recorded as recruiting^[11].
• Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients's study type is recorded as interventional study^[12].